{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:13Z","timestamp":1792979893404,"version":"4.5.0"},"reference-count":39,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Infection"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Influenza is a significant public health challenge, characterized by severe disease progression and considerable societal burden. Patients at high risk of influenza-related complications require special attention in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This study aimed to compare the effects of antiviral treatments for influenza on the incidence of bacterial complications, adverse events, and disease duration in high-risk outpatients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Multicenter, non-interventional, observational cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The study was conducted during the 2023\u20132024 influenza epidemic season and included 1867 high-risk outpatients treated with oseltamivir, umifenovir, kagocel, or imidazolyl ethanamide pentanedioic acid.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Bacterial complications occurred in 18.87% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009335) of high-risk patients, with 17.41% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009309) requiring antibacterial therapy. The hospitalization rate was 1.24% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200922), and the average disease duration was 8\u2009days. The incidence of bacterial complications varied among treatment groups: oseltamivir (18.96%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009102), umifenovir (12.17%%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200951), kagocel (22.00%%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009110), and imidazolyl ethanamide pentanedioic acid (22.64%%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200972). Adverse events were reported in 4.76% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200984) of patients, most commonly gastrointestinal disorders (91.67%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200977), followed by allergic reactions (8.33%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20097). The incidence of adverse events was significantly higher in the oseltamivir group compared to other treatments.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The etiotropic agents oseltamivir and umifenovir demonstrated comparable efficacy in managing influenza in high-risk patients, as reflected by their impact on bacterial complication rates and disease duration. Both drugs may be recommended for the treatment of high-risk influenza patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20499361251347726","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T22:47:46Z","timestamp":1750459666000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Antiviral therapy for influenza in high-risk outpatients: a multicenter observational study of routine clinical practice in Russia"],"prefix":"10.1177","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9824-3945","authenticated-orcid":false,"given":"Ivan","family":"Tokin","sequence":"first","affiliation":[{"name":"Smorodintsev Research Institute of Influenza, Saint Petersburg 197376, Russian Federation"},{"name":"North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Lioznov","sequence":"additional","affiliation":[{"name":"Smorodintsev Research Institute of Influenza, Saint Petersburg, Russian Federation"},{"name":"Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2004-3935","authenticated-orcid":false,"given":"Artem","family":"Poromov","sequence":"additional","affiliation":[{"name":"Mechnikov Research Institute of Vaccines and Sera, Moscow, Russian Federation"},{"name":"RUDN University, Moscow, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Zubkova","sequence":"additional","affiliation":[{"name":"Smorodintsev Research Institute of Influenza, Saint Petersburg, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5195-9316","authenticated-orcid":false,"given":"Valerii","family":"Tsvetkov","sequence":"additional","affiliation":[{"name":"Smorodintsev Research Institute of Influenza, Saint Petersburg, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olesya","family":"Nikitina","sequence":"additional","affiliation":[{"name":"Smorodintsev Research Institute of Influenza, Saint Petersburg, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Pobegalova","sequence":"additional","affiliation":[{"name":"Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Pshenichnaya","sequence":"additional","affiliation":[{"name":"Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Renev","sequence":"additional","affiliation":[{"name":"Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasiya","family":"Podgornaya","sequence":"additional","affiliation":[{"name":"Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"World Health Organization. Influenza (Seasonal) Fact sheet https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal) (2016 accessed 28 February 2025)."},{"issue":"2","key":"e_1_3_4_3_2","first-page":"7","article-title":"The effectiveness and safety of influenza vaccination in different populations","author":"Kostinov MP","year":"2011","unstructured":"Kostinov MP, Yerofeeva MK, Kharit SM. The effectiveness and safety of influenza vaccination in different populations. Terra Medica 2011; (2): 7\u201311.","journal-title":"Terra Medica"},{"key":"e_1_3_4_4_2","unstructured":"Global Influenza Strategy 2019-2030 World Health Organization https:\/\/www.who.int\/publications\/i\/item\/9789241515320 (15 March 2019)."},{"key":"e_1_3_4_5_2","unstructured":"The Federal State Budgetary Institution \u201cA.A. Smorodintsev Research Institute of Influenza\u201d of the Ministry of Health of Russian Federation. The influenza situation in Russia and in the world https:\/\/www.influenza.spb.ru\/en\/surveillance\/flu-bulletin\/"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.17116\/terarkh201789162-71"},{"key":"e_1_3_4_7_2","first-page":"24","author":"Influenza in adults","year":"2022","unstructured":"Influenza in adults. Clinical guidelines (approved by the Ministry of Health of the Russian Federation), 2022, pp. 24\u201336.","journal-title":"Clinical guidelines"},{"key":"e_1_3_4_8_2","first-page":"245","volume-title":"Influenza and other respiratory viral infections: epidemiology, prevention, diagnosis, and treatment","author":"Kiselev OI","year":"2003","unstructured":"Kiselev OI, Marinich IG, Sominina AA. Influenza and other respiratory viral infections: epidemiology, prevention, diagnosis, and treatment. Saint-Petersburg: Monographs, 2003, p. 245."},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1021\/cr800449m"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix1040"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62449-1"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00430-002-0139-9"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq012"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200326110-00004"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-016-2941-5"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.10.001"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix127"},{"key":"e_1_3_4_18_2","unstructured":"Instructions for the medical use of Arbidol. Instructions for the medical use of umifenovir imidazolyl ethanamide pentanedioic acid interferon gamma Kagocel ergoferon Tamiflu."},{"key":"e_1_3_4_19_2","unstructured":"On permission for medical use: Order of the Ministry of Health of the USSR dated 03\/23\/1988 No. 229."},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.2174\/092986708784049658"},{"key":"e_1_3_4_21_2","first-page":"93","volume-title":"Arbidol, immunomodulator, interferon inducer, antioxidant","author":"Glushkov RG","year":"1999","unstructured":"Glushkov RG, Guskova TA. Arbidol, immunomodulator, interferon inducer, antioxidant. Moscow: Timotek, 1999, p. 93."},{"key":"e_1_3_4_22_2","unstructured":"Influenza and acute respiratory viral infections: modern rational etiotropic and pathogenetic therapy. Algorithms for providing medical care to patients. Methodological guidelines. Moscow: Federal Medical and Biological Agency 2018. [Influenza and acute respiratory viral infections: modern rational etiotropic and pathogenetic therapy. Algorithms for rendering medical care to patients. Methodical recommendations]. Moscow: Federal Medical Biological Agency; 2018 (in Russ.)]."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.17116\/terarkh2017898113-119"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.17116\/terarkh2017891193-99"},{"key":"e_1_3_4_25_2","first-page":"26","article-title":"The possibilities of using the antiviral drug Kagocel\u00ae for the prevention and treatment of influenza and other acute respiratory infections in sickly young children\/\/effective pharmacotherapy","volume":"1","author":"Kharlamova FS","year":"2012","unstructured":"Kharlamova FS, Uchaykin VF, Sergeeva EM, et al. The possibilities of using the antiviral drug Kagocel\u00ae for the prevention and treatment of influenza and other acute respiratory infections in sickly young children\/\/effective pharmacotherapy. Epidemiol Infect 2012; 1: 26\u201334.","journal-title":"Epidemiol Infect"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.22328\/2413-5747-2019-5-3-68-76"},{"issue":"5","key":"e_1_3_4_27_2","first-page":"21","article-title":"Therapeutic efficacy of Kagocel in the treatment of patients with uncomplicated flu and flu complicated by angina","volume":"11","author":"Merkulova LN","year":"2002","unstructured":"Merkulova LN, Kolobukhina LV, Kisteneva LB, et al. Therapeutic efficacy of Kagocel in the treatment of patients with uncomplicated flu and flu complicated by angina. Clin pharmacol Ther 2002; 11(5): 21\u201323.","journal-title":"Clin pharmacol Ther"},{"key":"e_1_3_4_28_2","first-page":"34","article-title":"Clinical efficacy of Kagocel\u00ae in influenza and ARVI in children from 2 to 6 years old","volume":"4","author":"Kharlamova FS","year":"2010","unstructured":"Kharlamova FS, Kladova OV, Sergeeva EM, et al. Clinical efficacy of Kagocel\u00ae in influenza and ARVI in children from 2 to 6 years old. Children Infect 2010; 4: 34\u201341.","journal-title":"Children Infect"},{"key":"e_1_3_4_29_2","first-page":"36","article-title":"Evaluation of the therapeutic efficacy of Kagocel\u00ae in young and preschool children with acute respiratory viral infections","volume":"1","author":"Vartanyan RV","year":"2011","unstructured":"Vartanyan RV, Sergeeva EM, Cheshik SG. Evaluation of the therapeutic efficacy of Kagocel\u00ae in young and preschool children with acute respiratory viral infections. Children Infect 2011; 1: 36\u201341.","journal-title":"Children Infect"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.17116\/terarkh2016881168-75"},{"key":"e_1_3_4_31_2","first-page":"11","article-title":"The effect of antiviral therapy on the incidence of bacterial aggravations and administration of systemic antibiotics in patients with acute respiratory viral infections and influenza (results of international cohort observational study)","volume":"61","author":"Fazylov VCh","year":"2016","unstructured":"Fazylov VCh, Sitnikov IG, Malyshev NA, et al. The effect of antiviral therapy on the incidence of bacterial aggravations and administration of systemic antibiotics in patients with acute respiratory viral infections and influenza (results of international cohort observational study). Antibiot Chemother 2016; 61: 11\u201312.","journal-title":"Antibiot Chemother"},{"issue":"7","key":"e_1_3_4_32_2","first-page":"634","article-title":"The effect of the timing of initiation of therapy for acute respiratory viral infection and influenza on the dynamics of clinical symptoms and disease outcomes (results of the cohort international observational study FlU-eE)","volume":"96","author":"Sitnikov IG","year":"2017","unstructured":"Sitnikov IG, Fazylov VH, Silina EV, et al. The effect of the timing of initiation of therapy for acute respiratory viral infection and influenza on the dynamics of clinical symptoms and disease outcomes (results of the cohort international observational study FlU-eE). Clin Med 2017; 96(7): 634\u2013641. (In Russ.)","journal-title":"Clin Med"},{"key":"e_1_3_4_33_2","first-page":"57","article-title":"Analysis of drug therapy for ARVI and influenza and patient satisfaction with it: the results of the international cohort study FLU-EE","volume":"7","author":"Silina EV","year":"2017","unstructured":"Silina EV, Shevchenko SB, Groppa LG, et al. Analysis of drug therapy for ARVI and influenza and patient satisfaction with it: the results of the international cohort study FLU-EE. Lechaschi vrach 2017; 7: 57\u201364.","journal-title":"Lechaschi vrach"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.37489\/0235-2990-2020-65-1-2-15-20"},{"key":"e_1_3_4_35_2","volume-title":"A novel antiviral drug Ingavirin\u00ae restores the cellular antiviral response in influenza A virusinfected cells and enhances viral clearance in ferrets","author":"Egorov A.","year":"2013","unstructured":"Egorov A. A novel antiviral drug Ingavirin\u00ae restores the cellular antiviral response in influenza A virusinfected cells and enhances viral clearance in ferrets. Cape Town: Options for the control of influenza (VIII), 2013."},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.18093\/0869-0189-2013-0-6-43-50"},{"issue":"23","key":"e_1_3_4_37_2","first-page":"1","article-title":"Studying the efficacy and safety of a new antiviral drug Ingavirin\u00ae in the treatment of patients with influenza","volume":"16","author":"Kolobukhina LV","year":"2008","unstructured":"Kolobukhina LV, Malyshev NA, Merkulova LN, et al. Studying the efficacy and safety of a new antiviral drug Ingavirin\u00ae in the treatment of patients with influenza. Russian Med J 2008; 16(23): 1\u20135.","journal-title":"Russian Med J"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.18093\/0869-0189-2012-0-5-62-66"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.18093\/0869-0189-2012-0-4-62-69"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040296"}],"container-title":["Therapeutic Advances in Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20499361251347726","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20499361251347726","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20499361251347726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:01:32Z","timestamp":1777593692000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20499361251347726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":39,"alternative-id":["10.1177\/20499361251347726"],"URL":"https:\/\/doi.org\/10.1177\/20499361251347726","relation":{},"ISSN":["2049-9361","2049-937X"],"issn-type":[{"value":"2049-9361","type":"print"},{"value":"2049-937X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"article-number":"20499361251347726"}}